Search

Your search keyword '"Carrat, F"' showing total 890 results
Start Over Author "Carrat, F"
890 results on '"Carrat, F"'

101. Intensification with pegylated interferon during treatment with tenofovir in HIV–hepatitis B virus co‐infected patients

Author

Boyd, A., primary, Piroth, L., additional, Maylin, S., additional, Maynard‐Muet, M., additional, Lebossé, F., additional, Bouix, C., additional, Lascoux‐Combe, C., additional, Mahjoub, N., additional, Girard, P.‐M., additional, Delaugerre, C., additional, Carrat, F., additional, Lacombe, K., additional, and Miailhes, P., additional

Published
2016
Full Text
View/download PDF

104. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Author

Rondy, M., Launay, O., Puig-Barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, Katleen, Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-Domingo, J., Escribano-Lopez, B., Arnedo-Pena, A., Ruiz-Garcia, M., Tortajada-Girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-Gonzalez, R., Gil-Guillen, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-Baz, I., Cauda, Roberto, Donato, C., Santangelo, Rosaria, Perlasca, F., Fichera, Giovanni, Dara, M., Iacoviello, L., Olivieri, M., de Gaetano Donati K., Cauda R. (ORCID:0000-0002-1498-4229), Santangelo R. (ORCID:0000-0002-8056-218X), Fichera G., Rondy, M., Launay, O., Puig-Barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, Katleen, Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-Domingo, J., Escribano-Lopez, B., Arnedo-Pena, A., Ruiz-Garcia, M., Tortajada-Girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-Gonzalez, R., Gil-Guillen, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-Baz, I., Cauda, Roberto, Donato, C., Santangelo, Rosaria, Perlasca, F., Fichera, Giovanni, Dara, M., Iacoviello, L., Olivieri, M., de Gaetano Donati K., Cauda R. (ORCID:0000-0002-1498-4229), Santangelo R. (ORCID:0000-0002-8056-218X), and Fichera G.

Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Published
2015

106. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: A meta-analysis of A(H1N1)pdm09 serological studies from 19 countries

Author

Van Kerkhove, M.D. Hirve, S. Koukounari, A. Mounts, A.W. Allwinn, R. Bandaranayake Bella Bone, A. Carrat, F. Chadha, M.S. Chen, M. Chi, C.-Y. Cox Cretikos, M. Crowcroft, N. Cutter, J. Donnelly, C.A. de Lamballerie, X. Dellagi Doukas, G. Dudareva-Vizule, S. Ferguson, N.M. Fry, A.M. Gilbert, G.L. Haas, W. Hardelid, P. Horby, P. Huang, Q.S. Hungnes, O. Ikonen, N. Iwatsuki-Horimoto, K. Julkunen, I. Katz, J. Kawaoka, Y. Lalvani, A. Levy-Bruhl, D. Maltezou, H.C. McVernon, J. Miller, M. Mishra, A.C. Moghadami, M. Pawar, S.D. Reed, C. Riley, S. Rizzo, C. Rosella, L. Ross, T.M. Shu, Y. Skowronski, D.M. Sridhar, S. Steens, A. Tandale, B.V. Theodoridou, M. van Boven, M. Waalen, K. Wang, J.-R. Wu, J.T. Xu, C. Zimmer, S.

Abstract

Background: The global impact of the 2009 influenza A(H1N1) pandemic (H1N1pdm) is not well understood. Objectives: We estimate overall and age-specific prevalence of cross-reactive antibodies to H1N1pdm virus and rates of H1N1pdm infection during the first year of the pandemic using data from published and unpublished H1N1pdm seroepidemiological studies. Methods: Primary aggregate H1N1pdm serologic data from each study were stratified in standardized age groups and evaluated based on when sera were collected in relation to national or subnational peak H1N1pdm activity. Seropositivity was assessed using well-described and standardized hemagglutination inhibition (HI titers ≥32 or ≥40) and microneutralization (MN ≥ 40) laboratory assays. The prevalence of cross-reactive antibodies to the H1N1pdm virus was estimated for studies using sera collected prior to the start of the pandemic (between 2004 and April 2009); H1N1pdm cumulative incidence was estimated for studies in which collected both pre- and post-pandemic sera; and H1N1pdm seropositivity was calculated from studies with post-pandemic sera only (collected between December 2009-June 2010). Results: Data from 27 published/unpublished studies from 19 countries/administrative regions - Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, United Kingdom, United States, and Vietnam - were eligible for inclusion. The overall age-standardized pre-pandemic prevalence of cross-reactive antibodies was 5% (95%CI 3-7%) and varied significantly by age with the highest rates among persons ≥65 years old (14% 95%CI 8-24%). Overall age-standardized H1N1pdm cumulative incidence was 24% (95%CI 20-27%) and varied significantly by age with the highest in children 5-19 (47% 95%CI 39-55%) and 0-4 years old (36% 95%CI 30-43%). Conclusions: Our results offer unique insight into the global impact of the H1N1 pandemic and highlight the need for standardization of seroepidemiological studies and for their inclusion in pre-pandemic preparedness plans. Our results taken together with recent global pandemic respiratory-associated mortality estimates suggest that the case fatality ratio of the pandemic virus was approximately 0·02%. © 2013 John Wiley & Sons Ltd.

Published
2013

107. Histoire naturelle d'un virus zoonotique en mode insulaire : cas de la propagation du virus grippal pandémique H1N1p 2009 à La Réunion

Author

Cardinale, Eric, Pascalis, Hervé, Temmam, Sarah, Dsouli, N., Turpin, Magali, Rollot, O., Favier, F., Flahault, A., Carrat, F., De Lamballerie, Xavier, and Dellagi, Koussay

Subjects
S50 - Santé humaine, L73 - Maladies des animaux
Abstract

En mars 2009, un nouveau virus Influenza A a émergé au Mexique et aux Etats-Unis, caractérisé par une combinaison de segments génomiques d'origines humaine, porcine et aviaire. La diffusion très rapide de ce virus au reste du monde a spécifié la 1ère pandémie grippale du 21ème siècle. Le 1er cas confirmé à La Réunion, chez un voyageur en provenance d'Australie, date du 5 juillet 2009. Dès le 21 Juillet 2009, date du premier cas à transmission indigène rapporté par La CIRE-Réunion- Mayotte, le CRVOI et le CIC-EC de La Réunion ont lancé une enquête prospective en cohorte populationnelle, le programme CoPanFlu-Run. Son objectif est de décrire l'histoire naturelle de l'infection en population générale ainsi que mesurer les paramètres épidémiologiques, virologiques et sociologiques de l'épidémie. L'étude sérologique a révélé que La Réunion a été fortement impactée par l'épidémie grippale, surtout chez les enfants d'âge scolaire : près de 63% des moins de 20 ans ont séroconverti, un peu moins de 40% pour la tranche d'âge 20-59 ans, et 16,7% pour les plus de 60 ans. Comparés à l'estimation de la CIRE-Réunion-Mayotte qui annonce un taux d'attaque de 12.5% de formes symptomatiques ayant eu recours aux services sanitaires, ces résultats montrent la grande diffusion de l'épidémie sous forme peu ou pas symptomatique et sa grande bénignité à l'échelle communautaire. Notre étude montre par ailleurs que les taux d'anticorps au 1/40 cross réactants avec le virus pandémique présents éventuellement avant le passage épidémique protègent contre la séroconversion. L'étude virologique, a permis de détecter le virus pandémique dans les prélèvements nasaux de 71 individus dont la plupart étaient symptomatiques. Elle a en outre mis en évidence l'existence d'une co-circulation d'autres virus respiratoires (essentiellement rhinovirus et coronavirus) en population générale avant, pendant, et après le passage de la vague épidémique. Le séquençage de 28 souches de virus H1N1p 2009 détectées au sein de notre cohorte réunionnaise, a permis leur analyse phylogénétique. Les souches réunionnaises, bien qu'issues du clade 7 au niveau mondial, dans lequel, on retrouve les souches indiennes, australiennes et japonaises, forment un clade à part entière. Par ailleurs, il semble que l'origine des souches analysées n'est vraisemblablement pas australienne comme supposée au départ de l'épidémie, et qu'au moins 2 introductions concomitantes se sont produites à La Réunion. La première datant du 26 juin 2009, c'est-à-dire, 1 mois avant la datation de la circulation virale active estimée par la CIRE, et la seconde datant du 8 juillet 2009. Finalement, une fois que la vague épidémique en population s'est éteinte en moins de 9 semaines, l'étude du cheptel porcin a montré un passage substantiel chez l'animal qui se maintient jusqu'à ce jour. (Texte intégral)

Published
2011

108. P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study

Author

Boursier, J., primary, Veillon, P., additional, Vergniol, J., additional, Moal, V., additional, Dufour, C., additional, Bronowicki, J.-P., additional, Larrey, D., additional, Hézode, C., additional, Carrat, F., additional, Zoulim, F., additional, Fontaine, H., additional, Poynard, T., additional, Canva, V., additional, Cacoub, P., additional, Attali, P., additional, Bourlière, M., additional, Alric, L., additional, Zarski, J.-P., additional, Allam, S., additional, Calès, P., additional, and De Lédinghen, V., additional

Published
2015
Full Text
View/download PDF

110. P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER

Author

Carrat, F., primary, Haour, G., additional, Fontaine, H., additional, Dorival, C., additional, Simony, M., additional, Bourlière, M., additional, Capeau, J., additional, Carrieri, P., additional, Larrey, D., additional, Larsen, C., additional, Marcellin, P., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, De Ledinghen, V., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Jean-Pierre, Z., additional, and Pol, S., additional

Published
2015
Full Text
View/download PDF

111. O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Author

Bourliere, M., primary, Rabiega, P., additional, Ganne-Carrie, N., additional, Serfaty, L., additional, Marcellin, P., additional, Pouget, N., additional, Guyader, D., additional, Hezode, C., additional, Picon, M., additional, Causse, X., additional, Leroy, V., additional, Bronowicki, J.P., additional, Riachi, G., additional, Rosa, I., additional, Attali, P., additional, Molina, J.M., additional, Bacq, Y., additional, Tran, A., additional, Grangé, J.D., additional, Zoulim, F., additional, Fontaine, H., additional, Bertucci, I., additional, Bouvier-Alias, M., additional, Carrat, F., additional, and Benhamou, Y., additional

Published
2015
Full Text
View/download PDF

112. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

Author

Bronowicki, J.-P., primary, Fontaine, H., additional, Dufour, C., additional, Zoulim, F., additional, Larrey, D., additional, Canva, V., additional, Samuel, D., additional, Poynard, T., additional, Marcellin, P., additional, De Ledinghen, V., additional, Bourlière, M., additional, Alric, L., additional, Zarski, J.-P., additional, Raabe, J.-J., additional, Serfaty, L., additional, Metivier, S., additional, Riachi, G., additional, Abergel, A., additional, Loustaud-Ratti, V., additional, Causse, X., additional, Guyader, D., additional, Bernard, P.-H., additional, Attali, P., additional, Di Martino, V., additional, Cacoub, P., additional, Cales, P., additional, Tran, A., additional, Rosa, I., additional, Grando-Lemaire, V., additional, Portal, I., additional, Dao, T., additional, Lucidarme, D., additional, Fontanges, T., additional, Barthe, Y., additional, Pawlotsky, J.-M., additional, Pol, S., additional, Carrat, F., additional, and Hezode, C., additional

Published
2015
Full Text
View/download PDF

113. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Author

Hezode, C., primary, De Ledinghen, V., additional, Fontaine, H., additional, Zoulim, F., additional, Lebray, P., additional, Boyer, N., additional, Larrey, D., additional, Silvain, C., additional, Botta-Fridlund, D., additional, Leroy, V., additional, Bourliere, M., additional, D’Alteroche, L., additional, Hubert-Fouchard, I., additional, Guyader, D., additional, Rosa, I., additional, Nguyen-Khac, E., additional, Di Martino, V., additional, Carrat, F., additional, Fedchuk, L., additional, Akremi, R., additional, Bennai, Y., additional, and Bronowicki, J.-P., additional

Published
2015
Full Text
View/download PDF

115. LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

Author

Fontaine, H., primary, Hezode, C., additional, Zoulim, F., additional, Samuel, D., additional, Bourliere, M., additional, Haour, G., additional, Dorival-Mouly, C., additional, Leroy, V., additional, De Ledinghen, V., additional, Lucier, S., additional, Larrey, D., additional, Tran, A., additional, Metivier, S., additional, Benhamou, Y., additional, Hubert-Fouchard, I., additional, Habersetzer, F., additional, Marcellin, P., additional, Mathurin, P., additional, Alric, L., additional, Bronowicki, J.-P., additional, Guyader, D., additional, Loustaud-Ratti, V., additional, Minello, A., additional, Riachi, G., additional, Rosa, I., additional, Simony, M., additional, Diallo, A., additional, Carrat, F., additional, and Pol, S., additional

Published
2015
Full Text
View/download PDF

116. P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER

Author

De Ledinghen, V., primary, Fontaine, H., additional, Dorival, C., additional, Bourlière, M., additional, Larrey, D., additional, Marcellin, P., additional, Lucier, S., additional, Petrov-Sanchez, V., additional, Diallo, A., additional, Capeau, J., additional, Carrieri, P., additional, Larsen, C., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Zarski, J.-P., additional, Carrat, F., additional, and Pol, S., additional

Published
2015
Full Text
View/download PDF

117. LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*

Author

Pol, S., primary, Bourliere, M., additional, Lucier, S., additional, De Ledinghen, V., additional, Zoulim, F., additional, Dorival-Mouly, C., additional, Métivier, S., additional, Larrey, D., additional, Tran, A., additional, Hezode, C., additional, Bronowicki, J.-P., additional, Samuel, D., additional, Marcellin, P., additional, Zarski, J.-P., additional, Minello, A., additional, Alric, L., additional, Trinchet, J.-C., additional, Nahon, P., additional, Guyader, D., additional, Chazouillères, O., additional, Riachi, G., additional, Loustaud-Ratti, V., additional, Causse, X., additional, Mathurin, P., additional, Hubert-Fouchard, I., additional, Rosa, I., additional, Benhamou, Y., additional, Gournay, J., additional, Raabe, J.-J., additional, Raffi, F., additional, Petrov-Sanchez, V., additional, Diallo, A., additional, Fontaine, H., additional, and Carrat, F., additional

Published
2015
Full Text
View/download PDF

118. P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather

Author

Pol, S., primary, Lucier, S., additional, Fontaine, H., additional, Dorival, C., additional, Petrov-Sanchez, V., additional, Bourlière, M., additional, Capeau, J., additional, Carrieri, P., additional, Larrey, D., additional, Larsen, C., additional, Marcellin, P., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, De Ledinghen, V., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Zarski, J.-P., additional, and Carrat, F., additional

Published
2015
Full Text
View/download PDF

121. Évaluation de l’efficacité virologique et de la tolérance du traitement antiviral chez les patients porteurs d’une hépatite C chronique, associée à un lymphome B non hodgkinien : étude cas-témoins ANRS HC13 lympho-C

Author

Jeannel, J., primary, Bonnet, D., additional, Cacoub, P., additional, Pol, S., additional, Canioni, D., additional, Leblond, V., additional, Carrat, F., additional, Davi, F., additional, Hermine, O., additional, Besson, C., additional, and Alric, L., additional

Published
2014
Full Text
View/download PDF

122. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections

Author

Deuffic-Burban, S., Mohamed, M.K., Larouze, B., Carrat, F., Valleron, A.J., UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), and Legrand, Annette

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Published
2006

129. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt

Author

Bonnard, P., primary, Elsharkawy, A., additional, Zalata, K., additional, Delarocque-Astagneau, E., additional, Biard, L., additional, Le Fouler, L., additional, Hassan, A. B., additional, Abdel-Hamid, M., additional, El-Daly, M., additional, Gamal, M. E., additional, El Kassas, M., additional, Bedossa, P., additional, Carrat, F., additional, Fontanet, A., additional, and Esmat, G., additional

Published
2014
Full Text
View/download PDF

134. PO8 Étude cas-témoin mesurant l’efficacité du vaccin antigrippal saisonnier sur les formes sévères de grippe chez les patients diabétiques ou obèses

Author

Galtier, F., primary, Vanhems, P., additional, Loulergue, P., additional, Duval, X., additional, Postil, D., additional, Lenzi, N., additional, Foulongne, V., additional, Krivine, A., additional, Houhou, N., additional, Alain, S., additional, Valette, M., additional, Merle, C., additional, Carrat, F., additional, Lina, B., additional, and Launay, O., additional

Published
2014
Full Text
View/download PDF

135. Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study

Author

Simonsen, L, Spreeuwenberg, P, Lustig, R, Taylor, RJ, Fleming, DM, Kroneman, M, Van Kerkhove, MD, Mounts, AW, Paget, WJ, Echenique, H, Savy, V, Muscatello, D, MacIntyre, CR, Dwyer, DE, Azziz-Baumgartner, E, Homaira, N, Moura, FEA, Schuck, C, Akwar, H, Schanzer, D, Fuentes, R, Olea, A, Sotomayor, V, Feng, L, Yu, H, Mazick, A, Mølbak, K, Nielsen, J, Carrat, F, Lemaitre, M, Buchholz, U, Schweiger, B, Höhle, M, Vesenbeckh, S, Cowling, B, Leung, G, Tsang, T, Chuang, SK, Bromberg, M, Kaufman, Z, Sugaya, N, Oka Ezoe, K, Hayashi, S, Matsuda, M, Lopez-Gatell, H, Alpuche-Aranda, C, Noyola, D, Chowell, G, van Asten, L, Meijer, A, van den Wijngaard, K, van der Sande, M, Baker, M, Zhang, J, Benavides, JG, Munayco, C, Laguna-Torres, A, Rabczenko, D, Wojtyniak, B, Park, SH, Lee, YK, Zolotusca, L, Popovici, O, Popescu, R, Ang, LW, Cutter, J, Lin, R, Ma, S, Chen, M, Lee, VJ, Prosenc, K, Socan, M, Cohen, C, Larrauri, A, de Mateo, S, Méndez, LS, Sanz, CD, Andrews, N, Green, HK, Pebody, R, Saei, A, Shay, D, Viboud, C, Simonsen, L, Spreeuwenberg, P, Lustig, R, Taylor, RJ, Fleming, DM, Kroneman, M, Van Kerkhove, MD, Mounts, AW, Paget, WJ, Echenique, H, Savy, V, Muscatello, D, MacIntyre, CR, Dwyer, DE, Azziz-Baumgartner, E, Homaira, N, Moura, FEA, Schuck, C, Akwar, H, Schanzer, D, Fuentes, R, Olea, A, Sotomayor, V, Feng, L, Yu, H, Mazick, A, Mølbak, K, Nielsen, J, Carrat, F, Lemaitre, M, Buchholz, U, Schweiger, B, Höhle, M, Vesenbeckh, S, Cowling, B, Leung, G, Tsang, T, Chuang, SK, Bromberg, M, Kaufman, Z, Sugaya, N, Oka Ezoe, K, Hayashi, S, Matsuda, M, Lopez-Gatell, H, Alpuche-Aranda, C, Noyola, D, Chowell, G, van Asten, L, Meijer, A, van den Wijngaard, K, van der Sande, M, Baker, M, Zhang, J, Benavides, JG, Munayco, C, Laguna-Torres, A, Rabczenko, D, Wojtyniak, B, Park, SH, Lee, YK, Zolotusca, L, Popovici, O, Popescu, R, Ang, LW, Cutter, J, Lin, R, Ma, S, Chen, M, Lee, VJ, Prosenc, K, Socan, M, Cohen, C, Larrauri, A, de Mateo, S, Méndez, LS, Sanz, CD, Andrews, N, Green, HK, Pebody, R, Saei, A, Shay, D, and Viboud, C

Abstract

Background:Assessing the mortality impact of the 2009 influenza A H1N1 virus (H1N1pdm09) is essential for optimizing public health responses to future pandemics. The World Health Organization reported 18,631 laboratory-confirmed pandemic deaths, but the total pandemic mortality burden was substantially higher. We estimated the 2009 pandemic mortality burden through statistical modeling of mortality data from multiple countries.Methods and Findings:We obtained weekly virology and underlying cause-of-death mortality time series for 2005-2009 for 20 countries covering ∼35% of the world population. We applied a multivariate linear regression model to estimate pandemic respiratory mortality in each collaborating country. We then used these results plus ten country indicators in a multiple imputation model to project the mortality burden in all world countries. Between 123,000 and 203,000 pandemic respiratory deaths were estimated globally for the last 9 mo of 2009. The majority (62%-85%) were attributed to persons under 65 y of age. We observed a striking regional heterogeneity, with almost 20-fold higher mortality in some countries in the Americas than in Europe. The model attributed 148,000-249,000 respiratory deaths to influenza in an average pre-pandemic season, with only 19% in persons <65 y. Limitations include lack of representation of low-income countries among single-country estimates and an inability to study subsequent pandemic waves (2010-2012).Conclusions:We estimate that 2009 global pandemic respiratory mortality was ∼10-fold higher than the World Health Organization's laboratory-confirmed mortality count. Although the pandemic mortality estimate was similar in magnitude to that of seasonal influenza, a marked shift toward mortality among persons <65 y of age occurred, so that many more life-years were lost. The burden varied greatly among countries, corroborating early reports of far greater pandemic severity in the Americas than in Australia, New Zealand

Published
2013

137. Pandemic Influenza Due to pH1N1/2009 Virus: Estimation of Infection Burden in Reunion Island through a Prospective Serosurvey, Austral Winter 2009

Author

Dellagi, K, Rollot, O, Temmam, S, Salez, N, Guernier, Vanina, Pascalis, H, Gerardin, P, Fianu, A, Lapidus, N, Naty, N, Tortosa, P, Boussaid, K, Jaffar-Banjee, M-C, Filleul, L, Flahault, A, Carrat, F, Favier, F, de Lamballerie, X, Dellagi, K, Rollot, O, Temmam, S, Salez, N, Guernier, Vanina, Pascalis, H, Gerardin, P, Fianu, A, Lapidus, N, Naty, N, Tortosa, P, Boussaid, K, Jaffar-Banjee, M-C, Filleul, L, Flahault, A, Carrat, F, Favier, F, and de Lamballerie, X

Abstract

Background To date, there is little information that reflects the true extent of spread of the pH1N1/2009v influenza pandemic at the community level as infection often results in mild or no clinical symptoms. This study aimed at assessing through a prospective study, the attack rate of pH1N1/2009 virus in Reunion Island and risk factors of infection, during the 2009 season. Methodology/Principal Findings A serosurvey was conducted during the 2009 austral winter, in the frame of a prospective population study. Pairs of sera were collected from 1687 individuals belonging to 772 households, during and after passage of the pandemic wave. Antibodies to pH1N1/2009v were titered using the hemagglutination inhibition assay (HIA) with titers ≥1/40 being considered positive. Seroprevalence during the first two weeks of detection of pH1N1/2009v in Reunion Island was 29.8% in people under 20 years of age, 35.6% in adults (20–59 years) and 73.3% in the elderly (≥60 years) (P<0.0001). Baseline corrected cumulative incidence rates, were 42.9%, 13.9% and 0% in these age groups respectively (P<0.0001). A significant decline in antibody titers occurred soon after the passage of the epidemic wave. Seroconversion rates to pH1N1/2009 correlated negatively with age: 63.2%, 39.4% and 16.7%, in each age group respectively (P<0.0001). Seroconversion occurred in 65.2% of individuals who were seronegative at inclusion compared to 6.8% in those who were initially seropositive. Conclusions Seroincidence of pH1N1/2009v infection was three times that estimated from clinical surveillance, indicating that almost two thirds of infections occurring at the community level have escaped medical detection. People under 20 years of age were the most affected group. Pre-epidemic titers ≥1/40 prevented seroconversion and are likely protective against infection. A concern was raised about the long term stability of the antibody

Published
2011

144. 706 COMPARISON OF LIVER BIOPSY, ELASTOMETRY AND SERUM MARKERS FOR LIVER FIBROSIS ASSESSMENT IN GENOTYPE 4 HCV-INFECTED PATIENTS IN EGYPT. RESULTS OF THE ANRS12184 STUDY

Author

Bonnard, P., primary, El-Kassas, M., additional, Gamal, M., additional, Hassan, A.B., additional, Le Fouler, L., additional, Elsharkawy, A., additional, Delarocque-Astagneau, E., additional, El-Sayed, M., additional, Abd El Hay, A., additional, Abdel-Hamid, M., additional, Carrat, F., additional, Bedossa, P., additional, Mohamed, M., additional, Fontanet, A., additional, and Esmat, G., additional

Published
2013
Full Text
View/download PDF

145. 1429 BASELINE APOLIPOPROTEIN H (ApoH) IS A PREDICTOR OF EARLY VIROLOGIC RESPONSE TO TRIPLE THERAPY (ANRS CO20-CUPIC)

Author

Sultanik, P., primary, Mallet, V., additional, Dorival-Mouly, C., additional, Barthe, Y., additional, Fonaine, H., additional, Hézode, C., additional, Mottez, E., additional, Bronowicki, J.-P., additional, Carrat, F., additional, Gayat, E., additional, Casrouge, A., additional, Fontanet, A., additional, Theodorou, I., additional, Abel, L., additional, Pol, S., additional, and Albert, M., additional

Published
2013
Full Text
View/download PDF

147. 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

Author

Fontaine, H., primary, Hezode, C., additional, Dorival, C., additional, Larrey, D., additional, Zoulim, F., additional, De Ledinghen, V., additional, Canva, V., additional, Alric, L., additional, Bourlière, M., additional, Pol, S., additional, Poynard, T., additional, Riachi, G., additional, Bernard, P.-H., additional, Raabe, J.-J., additional, Gournay, J., additional, Métivier, S., additional, Pawlotsky, J.-M., additional, Samuel, D., additional, Barthe, Y., additional, Carrat, F., additional, and Bronowicki, J.-P., additional

Published
2013
Full Text
View/download PDF

148. 796 FACTORS ASSOCIATED WITH SUSTAINED VIROLOGICAL RESPONSE IN HCV/HIV PATIENTS RETREATED WITH PEG-INTERFERON-a2a-360 μg/wk AND RIBAVIRIN HIGH DOSE: RESULTS OF THE ANRS-HC-20 ETOC STUDY

Author

Bonnard, P., primary, Dominguez, S., additional, Driss, H., additional, Valantin, M.-A., additional, Lacombe, K., additional, Yazdanpanah, Y., additional, Pinta, A., additional, Pialoux, G., additional, Halfon, P., additional, Piroth, L., additional, Izopet, J., additional, and Carrat, F., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results